Updated RSV Vaccine and Immunisation Resources
12 Aug 2025
New respiratory syncytial virus (RSV) resources have been published, and existing resources updated to reflect the age extension of Arexvy among adults aged 50 to 59 years with medical risk conditions which increase the risk of severe disease.
There are also changes to wording around the upper gestational age for the administration of Abrysvo.
Department of Health, Disability and Ageing
ATAGI statement on RSV administration errors – new
RSV vaccine and monoclonal antibody poster – new
Respiratory syncytial virus (RSV) products – updated
RSV frequently asked questions – updated
RSV vaccine consumer fact sheet – updated
Australian Immunisation Handbook
Clinical guidance table – new
Respiratory syncytial virus (RSV) – updated
National Centre for Immunisation Research and Surveillance
RSV – frequently asked questions – updated
RSV immunisation products – updated
RSV immunisation products efficacy and safety – updated
NCIRS clinical guidance on administration errors – updated
This article appeared in Practice Pulse on Wednesday, 13 August 2025. If you are a GP, practice nurse or practice manager in South Western Sydney and do not get the weekly Practice Pulse email, speak to your Practice Support Officer.